Risk/Threat Assessment and Biosafety Studies

Gryphon’s threat and risk assessments enhance preparedness for natural and accidental outbreaks and intentional CBRN incidents. We have worked across the health security spectrum: assessing risks of emerging infectious diseases, guiding investments to minimize the risk of intentional CBRN attacks, and mitigating risks arising from laboratory research involving the most dangerous human and animal pathogens.

CASE STUDIES

01

Assessing the Risks and Benefits of Gain of Function Research

Gryphon performed a risk and benefit assessment of research on viruses with pandemic potential to inform the development of a new federal policy on review and oversight of that research. The quantitative risk assessment estimated the likelihood and consequences of research accidents and potential malicious use— including a first-of-its-kind examination of how human errors drive biosafety risk. The benefit assessment used a novel qualitative methodology to provide the most detailed benefits analysis of a field of scientific research ever undertaken.
02

Considering Risk in Configuring the Strategic National Stockpile (SNS)

Gryphon undertook a landmark, risk-based assessment of the SNS, the nation’s repository of medicines and supplies available for distribution in the event of a national emergency. For the first time, quantitative threat information was used to inform medical preparedness by identifying the formularies that would most reduce the risk from chemical, biological, radiological, and nuclear attacks. Our findings influenced several purchasing decisions for the SNS.
03

Predicting the Risk of Disease Spread

As part of a larger DTRA surveillance system, Gryphon developed a risk assessment application that predicts the likelihood that an outbreak of a person-to-person transmissible disease will spread to and throughout the United States. Several new features are under development including the risk of spread between any two countries, the risk of introduction and spread of vectors, and the risk of spread of novel infectious diseases.